These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 2033998)

  • 1. [The correlation between the serum concentrations of BCM (breast cancer mucin), CA549 and estradiol in women with breast macrocysts].
    Vizoso F; Allende MT; Fueyo A; Ruibal A
    Med Clin (Barc); 1991 Feb; 96(5):198. PubMed ID: 2033998
    [No Abstract]   [Full Text] [Related]  

  • 2. [Correlation of serum concentrations of BCM and MCA, CA 549 and CA 15.3 in women with macrocystic disease of breast].
    Vizoso F; Roiz MC; Allende MT; Ruibal A
    Med Clin (Barc); 1990 Mar; 94(8):319. PubMed ID: 2342398
    [No Abstract]   [Full Text] [Related]  

  • 3. [Correlations of serum concentrations of CA 15.3 and estradiol in women with breast macrocystic disease].
    Vizoso F; Allende MT; Fueyo A; Vivanco J
    Med Clin (Barc); 1990 May; 94(20):798. PubMed ID: 2392013
    [No Abstract]   [Full Text] [Related]  

  • 4. [Correlation between blood concentrations of CA 15.3 and estradiol in women with macrocystic disease of breast. Study in function of the type of cyst].
    Vizoso F; Allende MT; Díez MC; Ruibal A
    Rev Clin Esp; 1991 Nov; 189(8):390-1. PubMed ID: 1784805
    [No Abstract]   [Full Text] [Related]  

  • 5. Correlation between BCM (breast cancer mucin) and CA 549 serum levels cystic breast disease.
    Allende MT; Vizoso F; Roiz MC; Fueyo A; Ruibal A
    Int J Biol Markers; 1990; 5(1):48-9. PubMed ID: 2230352
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence of a correlation between CA15.3 and estradiol serum levels in women with fibrocystic (non macrocystic) mastopathy.
    Vizoso F; Allende MT; Diez MC; Ruibal A
    Int J Biol Markers; 1991; 6(1):33-4. PubMed ID: 1856515
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MCA performance in preoperative breast cancer patients.
    Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
    Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serum BCM in patients with nontumorous diseases. Preliminary results].
    Allende MT; Vizoso F; Sampedro A; Ruibal A
    Rev Clin Esp; 1990 Oct; 187(5):254-5. PubMed ID: 2102542
    [No Abstract]   [Full Text] [Related]  

  • 10. [Tumor markers in the diagnosis and prognosis of breast cancer].
    Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
    Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The correlation between the serum concentrations of CA 549 and CA 15.3 in patients with cystic breast disease].
    Allende MT; Vizoso F; Fueyo A; Ruibal A
    Rev Clin Esp; 1990; 187(3):152-3. PubMed ID: 2284494
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA.
    Gion M; Plebani M; Mione R; Penzo C; Meo S; Burlina A
    Br J Cancer; 1994 Apr; 69(4):721-5. PubMed ID: 8142260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Initial experiences with CA-15-3 determination in the serum of patients with breast cancer].
    Bartel U; Johannsen B; Reiss H; Elling D
    Zentralbl Gynakol; 1989; 111(21):1417-24. PubMed ID: 2557715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of serum CA549, CA M26 and CA M29 levels in the post-operative follow-up of breast cancer patients.
    Nicolini A; Ferdeghini M; Colombini C; Carpi A
    J Nucl Med Allied Sci; 1990; 34(4):309-13. PubMed ID: 2090796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
    Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
    Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between breast cancer mucin (BCM) and CA 125 serum levels in patients with active ovarian tumors.
    Roiz C; Allende T; Fernández-García J; Vivanco J; Bianco A; Ruibal A
    Int J Biol Markers; 1990; 5(4):207. PubMed ID: 2093735
    [No Abstract]   [Full Text] [Related]  

  • 17. Breast cancer mucin antigen (BCM) determination by IMX: a preliminary study of epidemiological distribution of the serum levels in gynecological diseases.
    Torre GC; Barbetti V; Lanfranco E; Robutti M; Foglia M; Corongiu F; Vigliercio GP
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):59-62. PubMed ID: 2092151
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum androgen levels and the menstrual cycle in women with benign or malignant breast disease.
    England PC; Sellwood RA; Knyba RE; Irvine JD
    Clin Oncol; 1981 Sep; 7(3):213-9. PubMed ID: 6211319
    [No Abstract]   [Full Text] [Related]  

  • 19. High BCM serum levels in patients with non breast tumors: first results.
    Allende T; Vizoso F; Roiz C; Fueyo A; Lennartz L; Ruibal A
    Bull Cancer; 1990; 77(10):1031-2. PubMed ID: 2249013
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum MCA, CA 125 and CA 19.9 determination in primary breast cancer.
    Yenisey C; Güner G
    Biochem Soc Trans; 1996 May; 24(2):302S. PubMed ID: 8736960
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.